The FDA can approve a weight-loss agent before cardiovascular outcome trial data mature a regulatory pathway that sets retatrutide on a plausible course toward a 2026 decision, assuming Phase 3 efficacy and safety data are filed by mid-2025
Patients have increasingly experienced issues such as tooth decay, gum irritation, enamel erosion, and persistent dry mouth while using GLP-1 drugs
Matrigel coating of organoids with iPSC-derived ECs from the same individual reportedly results in a vascularized brain organoid (Pham et al., 2018)
GLP-1 medications are designed to mimic this hormone, giving you a longer-lasting Im full feeling
10.1089/ars.2009.2973 36 Patio-CardonaS.Garrido-MiguelM.Pascual-MorenaC.Berlanga-MacasC.Lucern-Lucas-TorresM.Alfaro-GonzlezS.et al (2024)
Weve shared seven important tips to help doctors and patients deal with the challenges of B12 treatment